Notificação de entrada na fase nacional - PCT
#1.3
08/04/2026
RPI 2900
Application data
Number
112025019985Type
Filing
Publication
PCT
US2024020898 Examination has not been requested yet. Without that request by 03/21/2027, the application is definitively abandoned (art. 33 of the Brazilian IP Act).
Deadline to request examination:03/21/2027(208 days left)
Latest action published by the INPI: 08/04/2026. We update with every new RPI gazette, published weekly.
Applicants
EXELIXIS, INC.
US
Inventors
B. M. (pessoa física)
US
G. S. (pessoa física)
US
K. G. (pessoa física)
US
S. K. (pessoa física)
US
Y. M. (pessoa física)
US
IPC Classification
Priority claims
US
63/454,009 · 03/22/2023
Abstract
CONJUGADOS ANTICORPO-FÁRMACO DLL3 E USOS DESTES. A presente divulgação fornece conjugados anticorpo-fármaco DLL3 e seus usos.
Publications in the Brazilian Industrial Property Gazette (RPI).
#1.3
08/04/2026
RPI 2900
#1.1
09/30/2025
RPI 2856
From the same holder
Same category
Patent monitoring
Receive alerts on INPI events, decisions, and expiry dates for your portfolio.